Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peptideins: Navigating the gray zone of the proteome.

Trends in biochemical sciences·2026
Same author

Environmental Identification of Novel Enzymes for Polyurethane and Polyamide Degradation.

Angewandte Chemie (International ed. in English)·2026
Same author

"Too soon to tell"? The potential of tools like AggrescanAI for novel drug discovery and development.

Expert opinion on drug discovery·2026
Same author

Variant-dependent pharmacological rescue of phenylalanine hydroxylase supports a precision therapeutic strategy for phenylketonuria.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Plug-and-(Dis)Play Epitope Engineering on Ring-like Particles: Rational Design of Multivalent Immunoreagents for Diagnostics.

ACS applied bio materials·2026
Same author

Programmable CAR immunotherapies for neurodegenerative proteinopathies.

Trends in pharmacological sciences·2026

Related Experiment Video

Updated: Mar 6, 2026

High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay
12:55

High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay

Published on: June 1, 2014

24.6K

High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors.

Jordi Pujols1, Samuel Peña-Díaz2, María Conde-Giménez3

  • 1Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, 08193 Bellaterra, Spain. jordi.pujolspujol@gmail.com.

International Journal of Molecular Sciences
|March 4, 2017
PubMed
Summary

This study introduces a novel in-plate method to rapidly screen for alpha-synuclein (α-syn) aggregation inhibitors. This technique accelerates drug discovery for neurodegenerative diseases by overcoming limitations of traditional assays.

Keywords:
Parkinson diseaseamyloidhigh-throughput screeningprotein aggregationα-synuclein

More Related Videos

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

18.2K
Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
11:12

Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells

Published on: October 4, 2017

7.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay
12:55

High-throughput Functional Screening using a Homemade Dual-glow Luciferase Assay

Published on: June 1, 2014

24.6K
Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

18.2K
Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
11:12

Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells

Published on: October 4, 2017

7.7K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pharmacology

Background:

  • Neurodegenerative diseases are linked to abnormal protein aggregation in the brain.
  • Parkinson's disease involves alpha-synuclein (α-syn) aggregation into brain inclusions.
  • Inhibiting α-syn aggregation is a key therapeutic strategy for neurodegeneration.

Purpose of the Study:

  • To develop a fast, reproducible in-plate method for screening α-syn aggregation inhibitors.
  • To overcome the slow and irreproducible nature of conventional in vitro α-syn aggregation assays.
  • To facilitate high-throughput screening of large chemical libraries for potential drug candidates.

Main Methods:

  • Developed a simple, in-plate assay for monitoring α-syn aggregation kinetics.
  • Utilized recombinant alpha-synuclein protein for in vitro aggregation studies.
  • Applied the assay to screen a chemical library exceeding 14,000 compounds.

Main Results:

  • The novel method provides high reproducibility in monitoring α-syn aggregation.
  • The assay is faster and requires less protein compared to conventional methods.
  • Successfully identified potent α-syn aggregation inhibitors from a large chemical library.

Conclusions:

  • The developed in-plate assay is an effective tool for rapid, high-throughput screening of α-syn aggregation modulators.
  • This method significantly advances the search for disease-modifying agents for Parkinson's disease and related neurodegenerative disorders.
  • The approach enables efficient identification of promising compounds for further therapeutic development.